Novo Nordisk Total Liabilities 2010-2024 | NVO

Novo Nordisk total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Novo Nordisk total liabilities for the quarter ending March 31, 2024 were $29.121B, a 18.77% increase year-over-year.
  • Novo Nordisk total liabilities for 2023 were $30.191B, a 35.14% increase from 2022.
  • Novo Nordisk total liabilities for 2022 were $22.34B, a 13.46% increase from 2021.
  • Novo Nordisk total liabilities for 2021 were $19.691B, a 57.52% increase from 2020.
Novo Nordisk Annual Total Liabilities
(Millions of US $)
2023 $30,191
2022 $22,340
2021 $19,691
2020 $12,501
2019 $10,196
2018 $9,010
2017 $7,981
2016 $7,767
2015 $6,671
2014 $6,556
2013 $4,945
2012 $4,326
2011 $5,093
2010 $4,357
2009 $3,560
Novo Nordisk Quarterly Total Liabilities
(Millions of US $)
2024-03-31 $29,121
2023-12-31 $30,191
2023-09-30 $30,238
2023-06-30 $27,800
2023-03-31 $24,519
2022-12-31 $22,340
2022-09-30 $22,481
2022-06-30 $20,660
2022-03-31 $19,692
2021-12-31 $19,691
2021-09-30 $17,124
2021-06-30 $15,000
2021-03-31 $13,437
2020-12-31 $12,501
2020-09-30 $12,619
2020-06-30 $11,235
2020-03-31 $10,613
2019-12-31 $10,196
2019-09-30 $10,721
2019-06-30 $9,762
2019-03-31 $9,561
2018-12-31 $9,010
2018-09-30 $8,484
2018-06-30 $8,672
2018-03-31 $8,143
2017-12-31 $7,981
2017-09-30 $8,049
2017-06-30 $7,305
2017-03-31 $7,731
2016-12-31 $7,767
2016-09-30 $6,902
2016-06-30 $6,939
2016-03-31 $6,668
2015-12-31 $6,671
2015-09-30 $6,275
2015-06-30 $6,254
2015-03-31 $6,875
2014-12-31 $6,556
2014-09-30 $5,930
2014-06-30 $4,966
2014-03-31 $5,448
2013-12-31 $4,945
2013-09-30 $5,152
2013-06-30 $5,069
2013-03-31 $5,073
2012-12-31 $4,326
2012-09-30 $5,204
2012-06-30 $5,122
2012-03-31 $5,087
2011-12-31 $5,093
2011-09-30 $5,051
2011-06-30 $4,740
2011-03-31 $4,444
2010-12-31 $4,357
2010-09-30 $3,961
2010-06-30 $4,004
2010-03-31 $3,950
2009-12-31 $3,560
2009-09-30 $3,401
2009-06-30 $3,139
2009-03-31 $3,301
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $632.697B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $842.050B 121.70
Johnson & Johnson (JNJ) United States $355.659B 14.13
Merck (MRK) United States $328.429B 59.76
AbbVie (ABBV) United States $303.959B 15.70
AstraZeneca (AZN) United Kingdom $243.573B 21.17
Novartis AG (NVS) Switzerland $216.133B 15.32
Pfizer (PFE) United States $157.191B 19.53
Sanofi (SNY) $118.520B 11.18
Innoviva (INVA) United States $1.003B 7.05